[go: up one dir, main page]

WO2017215677A3 - Carbocisteine pharmaceutical composition and effects thereof for treating leukemia - Google Patents

Carbocisteine pharmaceutical composition and effects thereof for treating leukemia Download PDF

Info

Publication number
WO2017215677A3
WO2017215677A3 PCT/CN2017/097014 CN2017097014W WO2017215677A3 WO 2017215677 A3 WO2017215677 A3 WO 2017215677A3 CN 2017097014 W CN2017097014 W CN 2017097014W WO 2017215677 A3 WO2017215677 A3 WO 2017215677A3
Authority
WO
WIPO (PCT)
Prior art keywords
carbocisteine
pharmaceutical composition
effects
treating leukemia
leukemia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2017/097014
Other languages
French (fr)
Chinese (zh)
Other versions
WO2017215677A2 (en
Inventor
崔坤峰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2017215677A2 publication Critical patent/WO2017215677A2/en
Publication of WO2017215677A3 publication Critical patent/WO2017215677A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/11—Pteridophyta or Filicophyta (ferns)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

A carbocisteine pharmaceutical composition and use thereof in preparing medications for treating leukemia. The carbocisteine pharmaceutical composition provided in the present invention comprises carbocisteine and a naturally produced compound (I) extracted from dry leaves of Pyrrosia lingua. The carbocisteine pharmaceutical composition has more significant leukemia treatment effects than that of carbocisteine and of the natural product used separately.
PCT/CN2017/097014 2016-06-13 2017-08-11 Carbocisteine pharmaceutical composition and effects thereof for treating leukemia Ceased WO2017215677A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610412276.XA CN106074561A (en) 2016-06-13 2016-06-13 The pharmaceutical composition of carbocisteine and to leukemic therapeutical effect
CN201610412276.X 2016-06-13

Publications (2)

Publication Number Publication Date
WO2017215677A2 WO2017215677A2 (en) 2017-12-21
WO2017215677A3 true WO2017215677A3 (en) 2018-02-15

Family

ID=57846453

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2017/097014 Ceased WO2017215677A2 (en) 2016-06-13 2017-08-11 Carbocisteine pharmaceutical composition and effects thereof for treating leukemia

Country Status (2)

Country Link
CN (1) CN106074561A (en)
WO (1) WO2017215677A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105837422A (en) * 2016-04-20 2016-08-10 宋晓梅 Pharmaceutical composition of buprenorphine hydrochloride and application thereof in biomedicine
CN106074561A (en) * 2016-06-13 2016-11-09 崔坤峰 The pharmaceutical composition of carbocisteine and to leukemic therapeutical effect
CN106045835A (en) * 2016-06-23 2016-10-26 崔坤峰 Benserazide hydrochloride medicine composition and medical purpose therefore for decreasing blood glucose
CN106117166A (en) * 2016-06-23 2016-11-16 崔坤峰 The pharmaceutical composition of amrinone and the application in hypertension therapeutic thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102805746A (en) * 2011-06-02 2012-12-05 湖南九典制药有限公司 Compound pharmaceutical chemical acting on respiratory diseases and preparation process and application thereof
CN106074561A (en) * 2016-06-13 2016-11-09 崔坤峰 The pharmaceutical composition of carbocisteine and to leukemic therapeutical effect

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100584362C (en) * 2007-08-02 2010-01-27 徐平 Chinese medicine for treating leukemia

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102805746A (en) * 2011-06-02 2012-12-05 湖南九典制药有限公司 Compound pharmaceutical chemical acting on respiratory diseases and preparation process and application thereof
CN106074561A (en) * 2016-06-13 2016-11-09 崔坤峰 The pharmaceutical composition of carbocisteine and to leukemic therapeutical effect

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WANG YUANCHAO ET AL.: "Study on chemical constituents and pharmacological activities of Friedelane Triterpenes in Celastraceae", RESEARCH AND PRACTICE ON CHINESE MEDICINES, 31 December 2015 (2015-12-31), pages 73 - 79, ISSN: 1673-6427 *

Also Published As

Publication number Publication date
WO2017215677A2 (en) 2017-12-21
CN106074561A (en) 2016-11-09

Similar Documents

Publication Publication Date Title
ZA202103074B (en) Formulation based on medicinal plant, or part or extract thereof, use of the formulation and product including said formulation
SI3433256T1 (en) 6,7,8,9-tetrahydro-3h-pyrazolo(4,3-f)isoquinoline derivative useful in the treatment of cancer
EP4541361A3 (en) Treatment of cancer by manipulation of commensal microflora
WO2018067512A8 (en) Spirocyclic compounds
EP3398948A3 (en) 2,4,6,7-tetrasubstituted pteridine compounds and methods of synthesis and use thereof
WO2018023072A3 (en) Compounds and compositions and uses thereof
WO2017136450A3 (en) Compounds and methods of treating rna-mediated diseases
EP4520828A3 (en) Compositions and methods for the treatment of aberrant angiogenesis
WO2017215677A3 (en) Carbocisteine pharmaceutical composition and effects thereof for treating leukemia
EP4327887A3 (en) Fixed dose combinations and formulations comprising etc1002 and one or more statins and methods of treating or reducing the risk of cardiovascular disease
HK1254231A1 (en) Mito-honokiol compounds and methods of synthesis and use thereof
WO2016115054A3 (en) Modulators of ca2+ release-activated ca2+ (crac) channels and pharmaceutical uses thereof
WO2017220042A3 (en) Amrinone pharmaceutical composition and application thereof in hypertension treatment
WO2017079403A3 (en) Polymeric nanoparticles
FR3044226B1 (en) ALCOHOLIC EXTRACT OF AIR PARTS OF SOLIDAGO VIRGAUREA SUBSP. ALPESTRIS, METHOD FOR PRODUCING THE SAME, AND COSMETIC OR DERMATOLOGICAL COMPOSITION CONTAINING SAME
WO2017215678A3 (en) Cefaclor pharmaceutical composition and effects thereof for protecting acute lung injuries
SG11202104371XA (en) 1,3,4-oxadiazolone compound and pharmaceutical
EP3554496A4 (en) Methods and compositions for treating parkinson's disease
PH12016501205B1 (en) Catecholamine production accelerator, and therapeutic and preventive agent and therapeutic and preventive food composition for diseases caused by catecholamine deficiency
WO2016081671A8 (en) Pharmaceutical matrix formulations comprising dimethyl fumarate
EP3441076A4 (en) Pharmaceutical product for treating tumor and combined immune defect, and preparation and application thereof
EP3634979A4 (en) Compositions and methods for treating alzheimer's disease
HUE057090T2 (en) Bi-heteroaryl substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer
WO2018033742A3 (en) Cytisine derivatives for the treatment of addiction
WO2017160694A3 (en) Compositions for providing vitamin d to the skin

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17812788

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17812788

Country of ref document: EP

Kind code of ref document: A2

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 04/07/2019)

122 Ep: pct application non-entry in european phase

Ref document number: 17812788

Country of ref document: EP

Kind code of ref document: A2